Fetal haemoglobin variations following hydroxyurea treatment in patients with cyanotic congenital heart disease

P. Triadou, M. Maier-Redelsperger, R. Krishnamoorty, A. Deschamps, N. Casadevall, O. Dunda, R. Decrocq, J. Elion, R. Girot, D. Labie, George J Dover, P. Cornu

Research output: Contribution to journalArticle

Abstract

Haematological features of 64 patients suffering from non operable cyanotic congenital heart disease (CCHD) treated with hydroxyurea (HU) were compared with those of 43 patients suffering from the same disorder who had not yet received this drug. Patients with subclinical renal dysfunction were excluded by measuring plasma creatinine levels. MCV and HbF were higher among patients receiving HU, the increase in MCV being cumulative with HU dosage but the rise in HbF dose independent. HbF response to HU was found to be due to the coordinated increase in F-cell and F-reticulocyte production rather than to a selective survival of F-cells. Absence of a relationship between plasma erythropoietin and HbF levels excluded a dominant role of the former in increasing F-cell production and results determined after doubling the HU dosage or immediately after initiating therapy suggested genetic differences to be responsible for the individual variations in HbF response. No irreversible toxic effects or malignancies were noted in this series of patients. HU was administered for a relatively long period of time, the mean duration of treatment exceeding 5 years, while the study also included patients below the age of 10 years.

Original languageEnglish (US)
Pages (from-to)367-372
Number of pages6
JournalNouvelle Revue Francaise d'Hematologie
Volume36
Issue number5
StatePublished - 1994
Externally publishedYes

Fingerprint

Fetal Hemoglobin
Hydroxyurea
Heart Diseases
Therapeutics
Poisons
Reticulocytes
Erythropoietin
Genetic Therapy
Creatinine
Cell Survival
Kidney
Pharmaceutical Preparations
Neoplasms

Keywords

  • cyanotic congenital heart disease
  • fetal hemoglobin
  • hydroxyurea

ASJC Scopus subject areas

  • Hematology

Cite this

Triadou, P., Maier-Redelsperger, M., Krishnamoorty, R., Deschamps, A., Casadevall, N., Dunda, O., ... Cornu, P. (1994). Fetal haemoglobin variations following hydroxyurea treatment in patients with cyanotic congenital heart disease. Nouvelle Revue Francaise d'Hematologie, 36(5), 367-372.

Fetal haemoglobin variations following hydroxyurea treatment in patients with cyanotic congenital heart disease. / Triadou, P.; Maier-Redelsperger, M.; Krishnamoorty, R.; Deschamps, A.; Casadevall, N.; Dunda, O.; Decrocq, R.; Elion, J.; Girot, R.; Labie, D.; Dover, George J; Cornu, P.

In: Nouvelle Revue Francaise d'Hematologie, Vol. 36, No. 5, 1994, p. 367-372.

Research output: Contribution to journalArticle

Triadou, P, Maier-Redelsperger, M, Krishnamoorty, R, Deschamps, A, Casadevall, N, Dunda, O, Decrocq, R, Elion, J, Girot, R, Labie, D, Dover, GJ & Cornu, P 1994, 'Fetal haemoglobin variations following hydroxyurea treatment in patients with cyanotic congenital heart disease', Nouvelle Revue Francaise d'Hematologie, vol. 36, no. 5, pp. 367-372.
Triadou P, Maier-Redelsperger M, Krishnamoorty R, Deschamps A, Casadevall N, Dunda O et al. Fetal haemoglobin variations following hydroxyurea treatment in patients with cyanotic congenital heart disease. Nouvelle Revue Francaise d'Hematologie. 1994;36(5):367-372.
Triadou, P. ; Maier-Redelsperger, M. ; Krishnamoorty, R. ; Deschamps, A. ; Casadevall, N. ; Dunda, O. ; Decrocq, R. ; Elion, J. ; Girot, R. ; Labie, D. ; Dover, George J ; Cornu, P. / Fetal haemoglobin variations following hydroxyurea treatment in patients with cyanotic congenital heart disease. In: Nouvelle Revue Francaise d'Hematologie. 1994 ; Vol. 36, No. 5. pp. 367-372.
@article{04ebcabde7e34880ac0b141ed7aafd5f,
title = "Fetal haemoglobin variations following hydroxyurea treatment in patients with cyanotic congenital heart disease",
abstract = "Haematological features of 64 patients suffering from non operable cyanotic congenital heart disease (CCHD) treated with hydroxyurea (HU) were compared with those of 43 patients suffering from the same disorder who had not yet received this drug. Patients with subclinical renal dysfunction were excluded by measuring plasma creatinine levels. MCV and HbF were higher among patients receiving HU, the increase in MCV being cumulative with HU dosage but the rise in HbF dose independent. HbF response to HU was found to be due to the coordinated increase in F-cell and F-reticulocyte production rather than to a selective survival of F-cells. Absence of a relationship between plasma erythropoietin and HbF levels excluded a dominant role of the former in increasing F-cell production and results determined after doubling the HU dosage or immediately after initiating therapy suggested genetic differences to be responsible for the individual variations in HbF response. No irreversible toxic effects or malignancies were noted in this series of patients. HU was administered for a relatively long period of time, the mean duration of treatment exceeding 5 years, while the study also included patients below the age of 10 years.",
keywords = "cyanotic congenital heart disease, fetal hemoglobin, hydroxyurea",
author = "P. Triadou and M. Maier-Redelsperger and R. Krishnamoorty and A. Deschamps and N. Casadevall and O. Dunda and R. Decrocq and J. Elion and R. Girot and D. Labie and Dover, {George J} and P. Cornu",
year = "1994",
language = "English (US)",
volume = "36",
pages = "367--372",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Fetal haemoglobin variations following hydroxyurea treatment in patients with cyanotic congenital heart disease

AU - Triadou, P.

AU - Maier-Redelsperger, M.

AU - Krishnamoorty, R.

AU - Deschamps, A.

AU - Casadevall, N.

AU - Dunda, O.

AU - Decrocq, R.

AU - Elion, J.

AU - Girot, R.

AU - Labie, D.

AU - Dover, George J

AU - Cornu, P.

PY - 1994

Y1 - 1994

N2 - Haematological features of 64 patients suffering from non operable cyanotic congenital heart disease (CCHD) treated with hydroxyurea (HU) were compared with those of 43 patients suffering from the same disorder who had not yet received this drug. Patients with subclinical renal dysfunction were excluded by measuring plasma creatinine levels. MCV and HbF were higher among patients receiving HU, the increase in MCV being cumulative with HU dosage but the rise in HbF dose independent. HbF response to HU was found to be due to the coordinated increase in F-cell and F-reticulocyte production rather than to a selective survival of F-cells. Absence of a relationship between plasma erythropoietin and HbF levels excluded a dominant role of the former in increasing F-cell production and results determined after doubling the HU dosage or immediately after initiating therapy suggested genetic differences to be responsible for the individual variations in HbF response. No irreversible toxic effects or malignancies were noted in this series of patients. HU was administered for a relatively long period of time, the mean duration of treatment exceeding 5 years, while the study also included patients below the age of 10 years.

AB - Haematological features of 64 patients suffering from non operable cyanotic congenital heart disease (CCHD) treated with hydroxyurea (HU) were compared with those of 43 patients suffering from the same disorder who had not yet received this drug. Patients with subclinical renal dysfunction were excluded by measuring plasma creatinine levels. MCV and HbF were higher among patients receiving HU, the increase in MCV being cumulative with HU dosage but the rise in HbF dose independent. HbF response to HU was found to be due to the coordinated increase in F-cell and F-reticulocyte production rather than to a selective survival of F-cells. Absence of a relationship between plasma erythropoietin and HbF levels excluded a dominant role of the former in increasing F-cell production and results determined after doubling the HU dosage or immediately after initiating therapy suggested genetic differences to be responsible for the individual variations in HbF response. No irreversible toxic effects or malignancies were noted in this series of patients. HU was administered for a relatively long period of time, the mean duration of treatment exceeding 5 years, while the study also included patients below the age of 10 years.

KW - cyanotic congenital heart disease

KW - fetal hemoglobin

KW - hydroxyurea

UR - http://www.scopus.com/inward/record.url?scp=0028061495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028061495&partnerID=8YFLogxK

M3 - Article

C2 - 7534399

AN - SCOPUS:0028061495

VL - 36

SP - 367

EP - 372

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 5

ER -